Nuritas, a biotechnology company discovering life-changing drugs through the power of artificial intelligence (AI) based peptide discovery, today announced it will be presenting to and subsequently hosting an interactive workshop with global pharmaceutical industry leaders at the annual AI in Pharma Summit 2018 on Tuesday, October 9th, 2018 in Boston, MA.

“Artificial intelligence is an emerging technology with great promise in drug discovery,” said Emmet Browne, chief executive officer of Nuritas. “At Nuritas, we harness the power of AI to rapidly and efficiently discover peptide-based therapies for the world’s growing healthcare needs, with unmatched success rates across a broad range of disease areas. However, much work remains in understanding and maximizing the impact of this emerging technology.”

The workshop will explore how AI can be utilized to discover the next generation of therapeutics with reduced time and cost to foster industry discovery. Nuritas has attracted key global opinion leaders to participate in the panel discussions to understand how companies can collaborate within industry to bring better, safer and more affordable drugs to those most in need.

Nora Khaldi, Ph.D., founder and chief scientific officer of Nuritas, commented, “Nuritas has taken a leadership position at the AI in Pharma Summit to facilitate discussion with some of the world’s largest pharmaceutical companies. We are thrilled to be key sponsors of the innovative summit comprised of global leaders committed to bringing innovative, less expensive and safer new drugs to market. With drug prices spiraling, we now have the power, using AI, to significantly reduce discovery times and costs for more affordable drugs for patients globally. We look forward to bringing Nuritas’s unique perspective to the wider AI community.”

In addition to the workshop, Dr. Khaldi will give a presentation entitled “In Silico Predictions & In Vivo Correlations: The importance of Data Quality and Integrity in Driving AI empowered Discovery” as a part of the use case plenary session.

Workshop Pannelists: Nora Khaldi, Founder and Chief Scientific Officer, Nuritas, Vanita Sood, Global Head of Drug Structure, EMD Serono, Inc., John Baldoni, Senior Vice President, Head of In Silico Drug Discovery, GSK Pharma R&D, Lina Williamson, Director, Entrepreneurship & Innovation Translational Accelerator, Brigham and Women’s Hospital – Harvard University, Alan Kopin, Professor of Medicine and Director, Molecular Pharmacology Research Center, Tufts Medical Center and Agam Sheth, Director Enabling Technologies, Merck Research Laboratories, Merck & Co., Inc.

For more information:

https://www.aiinpharma.com 

Full agenda at:

https://www.aiinpharma.com/#agenda

Pin It on Pinterest

Share This